Scientific Reports · 2017 · 37 citations · 35 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacologyAntiviral TherapyTreatmentViral InfectionsAntiviral Structure-activity RelationshipsAntiviral TherapeuticsAntiviral TreatmentEarly Life InfectionHalogenated Natural ProductsTreatment Of Viral InfectionsViral Entry Inhibitors
Abstract Dengue virus infection is a global threat for which no specific treatment has not been established. Previous reports suggested chrysin and flavanone derivatives were potential flaviviral inhibitors. Here, we reported two halogenated chrysins, abbreviated FV13 and FV14, were highly potent against DENV1-4 and ZIKV infectivities with the FV13 EC 50 values of 2.30 ± 1.04, 1.47 ± 0.86, 2.32 ± 1.46, 1.78 ± 0.72 and 1.65 ± 0.86 µM; and FV14 EC 50 values of 2.30 ± 0.92, 2.19 ± 0.31, 1.02 ± 0.31, 1.29 ± 0.60 and 1.39 ± 0.11 µM, respectively. The CC 50 s to LLC/MK2 of FV13 and FV14 were 44.28 ± 2.90 μM, 42.51 ± 2.53 µM, respectively. Mechanism of drug action studies suggested multiple targets but maximal efficiency was achieved with early post infection treatment. This is the first report showing a high potency of halogenated chrysins for development as a broad-spectrum anti-flaviviral drug.
35
Daniel H. Libraty, Timothy P. Endy, Huo‐Shu H. Houng et al. · The Journal of Infectious Diseases · 2002 · 489 citations · Full text
Antiviral activity of four types of bioflavonoid against dengue virus type-2
Keivan Zandi, Boon‐Teong Teoh, Sing‐Sin Sam et al. · Virology Journal · 2011 · 428 citations · Full text
Tan Siew Kiat, Richard W. Pippen, Rohana Yusof et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 297 citations · Full text
Pei‐Yun Shu, Shu‐Fen Chang, Yu-Chung Kuo et al. · Journal of Clinical Microbiology · 2003 · 219 citations · Full text